Products for Research Use Only

BBO-8520

CAT: 0804-HY-158107-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-158107-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BBO-8520 is a direct small molecule covalent inhibitor targeting KRAS G12C with high oral availability. BBO-8520 has the characteristics of KRAS G12C (OFF) inhibitor and the function of blocking KRAS G12C (ON) signal. BBO-8520 inhibits cell proliferation by inhibiting KRAS G12C (ON) by binding GTP protein. BBO-8520 can block RAS-RAF1 interaction and return KRAS G12C to the inactive (OFF) state [1].
CAS Number
2893809-51-1
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bbo-8520.html
Purity
99.90
Solubility
DMSO : ≥ 50 mg/mL
Smiles
FC1=[C@](C(C(F)(F)F)=CC2=C(N=C(N=C21)OC[C@@]34CCCN3C[C@@H](C4)F)N5[C@H](CN([C@@H](C5)C)C(C=C)=O)C)[C@]6=CC=C(F)C7=C6C(C#N)=C(N)S7
Molecular Formula
C35H33F6N7O2S
Molecular Weight
729.74
References & Citations
[1]Maciag A E, et al. Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding[J]. Cancer Research, 2024, 84 (7_Supplement) : ND07-ND07.|[2]Caughey B A, Strickler J H. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies[J]. Drugs, 2024, 84 (1) : 27-44.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 1